Predictive Oncology Inc. (POAI)
POAI Stock Price Chart
Explore Predictive Oncology Inc. interactive price chart. Choose custom timeframes to analyze POAI price movements and trends.
POAI Company Profile
Discover essential business fundamentals and corporate details for Predictive Oncology Inc. (POAI) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Instruments & Supplies
IPO Date
3 May 2010
Employees
23.00
CEO
Raymond F. Vennare
Description
Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.
POAI Financial Timeline
Browse a chronological timeline of Predictive Oncology Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 May 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.09.
Earnings released on 13 Aug 2025
EPS came in at -$0.22 falling short of the estimated -$0.09 by -144.44%, while revenue for the quarter reached $2.68K , missing expectations by -99.82%.
Earnings released on 14 May 2025
EPS came in at -$0.32 falling short of the estimated -$0.09 by -255.56%, while revenue for the quarter reached $110.31K , missing expectations by -92.65%.
Earnings released on 27 Mar 2025
EPS came in at -$0.85 falling short of the estimated -$0.25 by -240.00%, while revenue for the quarter reached $611.59K , missing expectations by -59.23%.
Earnings released on 12 Nov 2024
EPS came in at -$0.36 falling short of the estimated -$0.32 by -12.50%, while revenue for the quarter reached $345.69K , missing expectations by -7.07%.
Earnings released on 13 Aug 2024
EPS came in at -$0.68 , while revenue for the quarter reached $278.72K , missing expectations by -25.07%.
Earnings released on 14 May 2024
EPS came in at -$1.04 , while revenue for the quarter reached $419.65K , beating expectations by +12.81%.
Earnings released on 28 Mar 2024
EPS came in at -$0.85 , while revenue for the quarter reached $335.03K , missing expectations by -9.94%.
Earnings released on 13 Nov 2023
EPS came in at -$0.78 , while revenue for the quarter reached $676.63K , beating expectations by +81.89%.
Earnings released on 10 Aug 2023
EPS came in at -$0.95 , while revenue for the quarter reached $490.11K , beating expectations by +31.75%.
Earnings released on 15 May 2023
EPS came in at -$0.86 , while revenue for the quarter reached $239.90K , missing expectations by -35.51%.
Stock split effective on 24 Apr 2023
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 21 Mar 2023
EPS came in at -$2.00 falling short of the estimated -$0.06 by -3.23K%, while revenue for the quarter reached $363.47K , missing expectations by -2.29%.
Earnings released on 10 Nov 2022
EPS came in at -$1.00 falling short of the estimated -$0.20 by -400.00%, while revenue for the quarter reached $455.83K , missing expectations by -88.60%.
Earnings released on 11 Aug 2022
EPS came in at -$1.00 falling short of the estimated -$0.60 by -66.67%, while revenue for the quarter reached $371.59K , missing expectations by -81.42%.
Earnings released on 12 May 2022
EPS came in at -$1.00 falling short of the estimated -$0.80 by -25.00%, while revenue for the quarter reached $314.57K , missing expectations by -68.54%.
Earnings released on 31 Mar 2022
EPS came in at -$1.20 falling short of the estimated -$0.23 by -420.00%, while revenue for the quarter reached $476.49K , missing expectations by -80.94%.
Earnings released on 10 Nov 2021
EPS came in at -$0.80 surpassing the estimated -$1.00 by +20.00%, while revenue for the quarter reached $313.66K , missing expectations by -16.67%.
Earnings released on 11 Aug 2021
EPS came in at -$1.00 surpassing the estimated -$1.40 by +28.57%, while revenue for the quarter reached $350.21K , beating expectations by +0.06%.
Earnings released on 12 May 2021
EPS came in at -$2.20 falling short of the estimated -$0.09 by -2.34K%, while revenue for the quarter reached $280.32K , beating expectations by +28.57%.
Earnings released on 15 Mar 2021
EPS came in at -$1.80 falling short of the estimated -$0.18 by -900.00%, while revenue for the quarter reached $293.79K .
Earnings released on 16 Nov 2020
EPS came in at -$5.20 , while revenue for the quarter reached $480.76K .
POAI Stock Performance
Access detailed POAI performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.